| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of CytoMed Therapeutics (NASDAQ:GDTC) through any online brokerage.
Other companies in CytoMed Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
CytoMed Therapeutics has a consensus price target of $5.00.
The stock price for CytoMed Therapeutics (NASDAQ: GDTC) is $0.869 last updated October 14, 2026 at 9:29 AM EDT.
There are no upcoming dividends for CytoMed Therapeutics.
CytoMed Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for CytoMed Therapeutics.
CytoMed Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
